In recognition of Dr. Jacques Michaud and Dr. Michael Sebag for their work on the CATALIS Quebec Board of Directors
After three years on the CATALIS Board of Directors, Dr. Jacques Michaud is now stepping down.
On behalf of the CATALIS Board of Directors, I would like to acknowledge Dr. Michaud’s professionalism and dedication, and to thank him for his great contribution to the development and growth of CATALIS. Dr. Michaud has contributed to the development and monitoring of the implementation of our 2020-2024 strategic plan, which aims to optimize the clinical research environment in Quebec and give patients the opportunity to benefit from innovative therapies and treatments.
Dr. Michaud is Chief of Division of Medical Genetics at CHU Sainte-Justine and Professor of Pediatrics and Neurosciences at the Faculty of Medicine of the Université de Montréal. Dr. Michaud’s clinical and research activities are focused on the genetics of neuro-developmental disorders. More specifically, his laboratory uses genomic approaches to identify genes involved in intellectual disability and epilepsy. As Scientific Director of the CHU Sainte-Justine and Génome Québec Integrated Clinical Genomics Centre in Pediatrics, Dr. Michaud also works on validating and integrating genomic tests that can be used in a clinical setting to better understand rare diseases.
My colleagues on the Board of Directors and the management of CATALIS join me in expressing our gratitude to Dr. Michaud for his contribution to our organization and in wishing him the best of success in his future professional and academic endeavors.
We would also like to thank Dr. Michael Sebag for his contribution to the Board of Directors since June 2020. Although Dr. Sebag is stepping down from the CATALIS Board of Directors, he will now be serving on our Scientific Advisory Committee.
Dr. Sebag is a hematologist at the Research Institute of the McGill University Health Centre (RI-MUHC). He has been working towards improving the lives of patients with multiple myeloma and related disorders since 2006, including through the preclinical development of new drugs that target largely unexploited pathways in multiple myeloma. In addition, he is involved in the development of investigator-led clinical trials across Canada.
We thank Dr. Sebag for his work on the CATALIS Board of Directors and are happy that he will continue to share his expertise and support the development of our organization by serving on the Scientific Advisory Committee.
– Marc Rivière, President of the CATALIS Quebec Board of Directors
